&lt;h2&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;OVERVIEW&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Eculizumab, a monoclonal antibody that targets complement component C5, is a revolutionary treatment for PNH, aHUS, and other disorders. Administered intravenously, dosing depends on the specific condition. It is usually well-tolerated, though some adverse effects may occur. Therapeutic drug monitoring assists in personalizing treatment, including dose adjustments or discontinuation during remission. Evaluating complement blockage helps determine the effectiveness of the therapy.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;hr /&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;METHOD NAME&lt;/span&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;EAH50: Enzyme-Linked Immunosorbent Assay (ELISA)&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;ECULI: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS), High Resolution Accurate Mass&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;AVAILABILITY&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;TBC&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;REPORTING NAME&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Eculizumab Monitoring Panel, S&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;ALIASES&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;ECULI&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Eculizumab&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;ECUMP&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Soliris&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Alexion&lt;/span&gt;&lt;/p&gt;

&lt;h3&gt;&amp;nbsp;&lt;/h3&gt;
&lt;h3 id=&quot;SpecimenType-title&quot;&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;SPECIMEN TYPE&lt;/strong&gt;&amp;nbsp;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Serum&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Serum Red&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;SHIPPING INSTRUCTIONS&lt;/span&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;TBC&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;span style=&quot;color: #ff99cc;&quot;&gt;&lt;strong&gt;SPECIMEN REQUIRED&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Patient Preparation:&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Fasting preferred.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Suggest discontinuing natalizumab at least 4 weeks prior to testing for eculizumab quantitation in serum. Patient should consult the healthcare provider who prescribed this drug to determine if discontinuation is an option. If not, ok to proceed with testing while taking natalizumab.&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Supplies:&amp;nbsp;&lt;/strong&gt;Sarstedt Aliquot Tube, 5 mL&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Collection Container/Tube:&lt;/strong&gt;&amp;nbsp;Red top (serum gel/SST are&amp;nbsp;&lt;strong&gt;not acceptable&lt;/strong&gt;)&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Submission Container/Tube:&lt;/strong&gt;&amp;nbsp;2 Plastic vials&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Specimen Volume:&lt;/strong&gt;&amp;nbsp;2 mL in 2 plastic vials, each vial containing 1 mL&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;&lt;strong&gt;Collection Instructions:&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Draw blood immediately before next scheduled dose.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Immediately after specimen collection, place the tube on wet ice.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;After sample has clotted on wet ice, centrifuge at 4 degrees C and aliquot serum into two 5 mL plastic vials.&lt;/span&gt;&lt;/li&gt;
&lt;li style=&quot;font-weight: 400;&quot;&gt;&lt;span style=&quot;color: #99ccff;&quot;&gt;Freeze specimen within 30 minutes of centrifugation. Sample must be placed on dry ice if not frozen immediately.&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

Lysosomal and Peroxisomal Disorders Screen, Blood Spot

Lysosomal Storage Disease Gene Panel, Varies

Eculizumab Monitoring Panel, Serum